UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy

Journal of thoracic oncology, 2009-12, Vol.4 (12), p.1590-1591

2009

Volltextzugriff (PDF)

Pemetrexed Induced Pneumonitis

Clinics and practice, 2011-11, Vol.1 (4), p.e106

2011

Volltextzugriff (PDF)

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer

Journal of thoracic oncology, 2008-01, Vol.3 (1), p.59-67

2008

Volltextzugriff (PDF)

Diagnosis to Treatment Interval and Outcome in Patients with Locally-Advanced Squamous Cell Carcinoma of the Head and Neck in a Veterans Affairs Medical Center

Journal of cancer science & therapy, 2012, Vol.4 (5)

2012

Volltextzugriff (PDF)

Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer

Journal of thoracic oncology, 2006-03, Vol.1 (3), p.245-251

2006

Volltextzugriff (PDF)

Forthcoming receptor tyrosine kinase inhibitors

Expert opinion on therapeutic targets, 2006-12, Vol.10 (6), p.793-797

2006

Volltextzugriff (PDF)

Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer

Clinical lung cancer, 2005-12, Vol.7 Suppl 3, p.S98-S104

2005

Volltextzugriff (PDF)

67-Year-Old Man With Hepatitis C Infection and Abdominal Distention

Mayo Clinic proceedings, 2003-02, Vol.78 (2), p.217-220

2003

Volltextzugriff (PDF)

A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS3620-TPS3620

2018

Volltextzugriff (PDF)

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

Cancer chemotherapy and pharmacology, 2015-11, Vol.76 (5), p.917-924

2015

Volltextzugriff (PDF)

Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics

Clinical pharmacology in drug development, 2021-02, Vol.10 (2), p.144-152

2021

Volltextzugriff (PDF)

28-Year-Old Man With Recurrent Fever

Mayo Clinic proceedings, 2003-07, Vol.78 (7), p.897-900

2003

Volltextzugriff (PDF)

Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF -mutant melanoma

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.9020-9020

2015

Volltextzugriff (PDF)

E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9091-9091

2016

Volltextzugriff (PDF)

Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF -mutant melanoma

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.9510-9510

2016

Volltextzugriff (PDF)

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.2573-2573

2015

Volltextzugriff (PDF)

Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF -mutated melanoma patients (pts) treated in the coBRIM study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.9033-9033

2015

Volltextzugriff (PDF)

Small cell carcinoma of the urinary bladder

Cancer, 2005-03, Vol.103 (6), p.1172-1178

2005

Volltextzugriff (PDF)

Continuous-Course Reirradiation With Concurrent Carboptatin and Paclitaxel for Locally Recurrent, Nonmetastatic Squamous Cell Carcinoma of the Head-and-Neck

International journal of radiation oncology, biology, physics, 2012, Vol.83 (2), p.690-695

2012

Volltextzugriff (PDF)

Combination of vemurafenib and cobimetinib in patients with advancedBRAFV600-mutated melanoma: a phase 1b study

The lancet oncology, 2014-08, Vol.15 (9), p.954

2014

Volltextzugriff (PDF)

How safe is surgery in obese lung cancer patients?

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e17555-e17555

2012

Volltextzugriff (PDF)

Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.9006-9006

2014

Volltextzugriff (PDF)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)

Journal of translational medicine, 2014-05, Vol.12 (Suppl 1), p.O7-O7

2014

Volltextzugriff (PDF)

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

The New England journal of medicine, 2014, Vol.371 (20), p.1867-1876

2014

Volltextzugriff (PDF)

Stereotactic radiosurgery for the management of brain metastases

The New England journal of medicine, 2010-08, Vol.363 (6), p.592; author reply 592

2010

Volltextzugriff (PDF)

26 – 50 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(139)
Mit Volltextzugriff
(123)

Publikationsform

Sprache

Englisch
(147)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy

Pemetrexed Induced Pneumonitis

Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer

Diagnosis to Treatment Interval and Outcome in Patients with Locally-Advanced Squamous Cell Carcinoma of the Head and Neck in a Veterans Affairs Medical Center

Phase II Trial of Temozolomide and Irinotecan as Second-Line Treatment for Advanced Non–small Cell Lung Cancer

Forthcoming receptor tyrosine kinase inhibitors

Adjuvant and neoadjuvant therapy for early-stage non-small-cell lung cancer

67-Year-Old Man With Hepatitis C Infection and Abdominal Distention

A randomized phase II study of trastuzumab and pertuzumab (TP) compared to cetuximab and irinotecan (CETIRI) in advanced/metastatic colorectal cancer (mCRC) with HER2 amplification: S1613

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

Effect of Hepatic Impairment on Cobimetinib Pharmacokinetics: The Complex Interplay Between Physiological Changes and Drug Characteristics

28-Year-Old Man With Recurrent Fever

Extended follow-up results of phase Ib study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF -mutant melanoma

E3508: Randomized trial of carboplatin (C), paclitaxel (P), bevacizumab (B) with or without cixutumumab (Cx) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC)

Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF -mutant melanoma

Population pharmacokinetics and dosing implications for cobimetinib in patients with solid tumors

Clinical features of cobimetinib (COBI)–associated serous retinopathy (SR) in BRAF -mutated melanoma patients (pts) treated in the coBRIM study

Small cell carcinoma of the urinary bladder

Continuous-Course Reirradiation With Concurrent Carboptatin and Paclitaxel for Locally Recurrent, Nonmetastatic Squamous Cell Carcinoma of the Head-and-Neck

Combination of vemurafenib and cobimetinib in patients with advancedBRAFV600-mutated melanoma: a phase 1b study

How safe is surgery in obese lung cancer patients?

Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7)

Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Stereotactic radiosurgery for the management of brain metastases

Suchergebnisse filtern